a

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem nulla consequat. Aenean massa.

SELAMAT HARI RAYA AIDILADHA 1442H FROM CIC

Greeting from CIC, We would like to take this opportunity to extend our sincere gratitude and appreciation for your kind support to CIC all this while. Wishing everyone a festive Eid al-Adha and Happy Holiday Warm regards, Clinical Investigation Centre #1metre #Physicaldistancing #FollowSOP #Wearmask #kitajagakita #kitamestimenang #LeaderinClinicalResearch #ClinicalInvestigationCentre #clinicaltrial #CICUMMC […]

CIC GOOD CLINICAL PRACTICE (GCP) WORKSHOP POSTPONEMENT

Greetings from CIC! Following the current pandemic situation and MCO status in Malaysia, all face-to-face workshops must be postponed until further notice. We are looking at tentatively conduct it at end of August, however, it is subjected to the MCO situation then. Any updates will be posted both on our Google [...]

CONGRATULATION FOR ACHIEVING SITE’S TARGET WITHIN THE STIPULATED TIMELINE [QUASAR]

Congratulations Prof. Dr. Ida Normiha Hilmi and the study team for achieving the site’s target within the stipulated timeline for QUASAR study! Your hard work and dedication are deeply meaningful to UMMC and the nation. Details of the study: https://clinicaltrials.gov/ct2/show/NCT04033445

Congratulation on First Site to Enroll the First Subject in Malaysia [ARC-10]

Congratulations Assoc. Prof. Dr. Ho Gwo Fuang and the study team for the great achievement on the first recruitment in Malaysia for the ARC-10 study! Your hard work and effort are deeply meaningful to UMMC and the nation. Details of the study: https://clinicaltrials.gov/ct2/show/NCT04736173

VOLUNTEERS FOR COVID-19 VACCINE

As announced by the Ministry of Health (MOH), there is an additional one (1) clinical trial study involving the COVID-19 vaccine that has been approved by the National Pharmaceutical Regulatory Division (NPRA) on 28 May 2021. This clinical study involves the product SARS-CoV-2 Vaccine ( Vero Cells), Inactivated, 5μg/0.5mL. Manufactured […]

COVID-19 INFORMATION: MOVEMENT CONTROL ORDERS (MCO) 3.0

COVID-19 INFORMATION: MOVEMENT CONTROL ORDERS (MCO) 3.0 The Malaysian government has announced Movement Control Order (MCO) 3.0 from 25th May 2021 until 7th June 2021. CIC management will continue to facilitate the Study Team, CRA and Sponsors by allowing for an on-site monitoring visit. CRA/Sponsor must conduct all Qualification visit […]

CLINICAL TRIALS FACTSHEET ON COVID-19 WORLDWIDE BY DR. PHAN CHIA WEI, HEAD OF CIC

Factsheet written by Dr Phan Chia Wei, Head of CIC, on clinical trials on COVID-19 worldwide. The factsheet is published by the Academy of Science Malaysia (ASM) in collaboration with the Young Scientists Network (YSN). To add, we would like to express our heartiest congratulations to a new clinical trial […]

UM LEADS CLINICAL TRIALS FOR TOCILIZUMAB IN COVID-19 TREATMENT

Malaysia is embarking on a clinical study to evaluate the drug Tocilizumab for the treatment of severe cases of Covid-19. Led by Universiti Malaya Faculty of Medicine dean Professor Datuk Dr Adeeba Kamarulzaman, the trial is underway at Universiti Malaya Medical Centre (UMMC), together with three public hospitals: Sungai Buloh […]

UMMC, MOH HOSPITALS STUDYING ARTHRITIS DRUG TREATMENT FOR SEVERE COVID-19

Great news and new hope! CIC and the UMMC Covid-19 special taskforce go full force looking for new treatment for Covid-19 patients. “UMMC has already used tocilizumab (trade name Actemra) on several Covid-19 patients who developed “cytokine storm” syndrome, a dangerous overreaction of the immune system, resulting in respiratory and […]

New Cancer Treatment Machine in Clinical Investigation Centre

Clinical Investigation Centre has installed a new cancer treatment machine – REMISSION1°C. What is REMISSION1°C? It is a high frequency hyperthermia equipment. The working principle through application of high frequency electric energy into the body, the frictional heat is generated by the molecular movements such as their rotation, friction, twist, or collision. […]